FOXE2 Activators
FOXE2 Activators are a class of compounds that interact with various cellular signaling pathways to enhance the functional activity of the transcription factor FOXE2. Forskolin, by increasing intracellular cAMP levels, leads to the activation of PKA, which can phosphorylate transcriptional co-activators that interact with FOXE2, thereby enhancing its transcriptional activity. Inhibition of GSK-3β by Lithium Chloride leads to increased levels of β-catenin, a co-activator of FOXE2, thus amplifying FOXE2's transcriptional effects. Retinoic Acid, through its receptors, facilitates the formation of transcriptionally active complexes that can include FOXE2, bolstering its ability to regulate gene expression.Trichostatin A, as a histone deacetylase inhibitor, promotes a more transcriptionally active chromatin environment, thus facilitating FOXE2's access to DNA and enhancing its functional activity. IBMX, by maintaining elevated cAMP levels, ensures prolonged PKA activity, which positively affects FOXE2's transcriptional machinery. The use of 5-Aza-2'-deoxycytidine leads to hypomethylation of DNA, allowing FOXE2 to more effectively engage with its target genes, potentiating its role in transcriptional regulation.
PI-103 and LY294002, both PI3K inhibitors, modulate the AKT signaling pathway, creating a cellular context that enhances the activity of FOXE2 through altered phosphorylation of its interaction partners. CDK4/6 inhibition by PD 0332991 results in an upregulation of FOXE2 activity during the G1 phase of the cell cycle, a critical time for FOXE2-mediated transcription. SP600125's inhibition of JNK alters the activity of AP-1 transcription factors, which can compete or cooperate with FOXE2 at certain gene promoters, enhancing FOXE2's transcriptional impact. Rapamycin's inhibition of mTOR affects the stability and translation of proteins that associate with FOXE2, leading to an indirect enhancement of FOXE2's transcriptional effects. Lastly, Chetomin disrupts HIF-p300 interactions, which can result in increased availability of p300 for FOXE2, thus augmenting its transcriptional activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin activates adenylate cyclase, increasing cAMP levels. cAMP is a second messenger that can enhance FOXE2 activity by promoting PKA-mediated phosphorylation of transcription factors and co-activators that interact with FOXE2, leading to its enhanced transcriptional activity. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium Chloride inhibits GSK-3β, which can lead to the stabilization and nuclear accumulation of β-catenin, a co-activator of FOXE2. The accumulation of β-catenin in the nucleus can enhance FOXE2 transcriptional activity by facilitating the formation of transcriptionally active complexes. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor, which leads to an open chromatin structure and enhanced access of transcription factors like FOXE2 to their target DNA sequences, thus increasing FOXE2-driven transcriptional activity. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX is a phosphodiesterase inhibitor that prevents cAMP degradation, leading to sustained PKA activation. PKA can phosphorylate proteins that regulate FOXE2's transcriptional activity, leading to its enhancement. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $214.00 $316.00 $418.00 | 7 | |
5-Aza-2'-deoxycytidine inhibits DNA methyltransferases, leading to decreased DNA methylation and a more open chromatin state. This can enhance the binding of FOXE2 to its target gene promoters, increasing its functional activity. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $32.00 $128.00 | 3 | |
PI-103 is a PI3K inhibitor that can lead to altered AKT signaling, which indirectly influences FOXE2 by modulating the phosphorylation state of proteins that interact with FOXE2, leading to its enhanced activity. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
PD 0332991 is a CDK4/6 inhibitor that can lead to cell cycle arrest in the G1 phase, during which FOXE2 transcriptional activity is crucial. This can result in the upregulation of FOXE2 target genes due to reduced competition for E2F binding sites. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that, by reducing AKT activity, can enhance FOXE2 activity through the modulation of FOXE2's interaction with other transcription factors and co-regulators affected by the PI3K/AKT pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that can influence AP-1 activity. AP-1 factors can interact with FOXE2 at promoter sites, and their inhibition can enhance FOXE2's binding and transcriptional activity on shared target genes. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which can influence the translation and stability of proteins that interact with FOXE2. Inhibition of mTOR can enhance FOXE2 transcriptional activity by affecting the availability and function of these interacting proteins. | ||||||